Barriers and facilitators of visceral leishmaniasis case management in the Amhara Region, Northwest Ethiopia: an exploratory qualitative study.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
13 Sep 2024
Historique:
received: 12 03 2024
accepted: 11 09 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 13 9 2024
Statut: epublish

Résumé

Visceral leishmaniasis (VL) is among the world's most serious public health threats, causing immense human suffering and death. In Ethiopia, little is known about the barriers and facilitators of visceral leishmaniasis case management. This study aimed to explore such barriers and facilitators in the Amhara Regional State, Northwest Ethiopia. An exploratory qualitative study was conducted on 16 purposively selected patients and key informants from May 8 to June 2, 2023. The study participants were recruited using the maximum variation technique. The interviews were audio recorded, transcribed verbatim, and translated into English. Thematic analysis was employed using Atlas.ti 9 software with a blended approach of both deductive and inductive coding. The study identified a variety of issues that hinder the success of visceral leishmaniasis case management. Treatment centers face frequent interruptions of medicinal supplies, a lack of funding, and a lack of trained healthcare providers. A lack of support from health authorities, including weak supervision and feedback systems, is also a source of concern. Most patients receive treatments after significant delays, which is primarily due to low awareness, poor surveillance, and misdiagnosis by healthcare workers. The case management is further constrained by malnutrition, VL-HIV co-infection, and other comorbidities. Despite these issues, we found that effective collaboration between hospital units and VL treatment centers, acceptance by hospitals, and the caring attitude of healthcare workers play a positive role in facilitating the program's effectiveness. Despite the existence of certain efforts that facilitate the program's effectiveness, VL remains largely neglected, with little government attention or intervention. Such inattention is the root cause of most of the issues. Despite limited resources, most issues could be resolved with cost-effective strategies if health authorities at all levels have the will and commitment to do so.

Sections du résumé

BACKGROUND BACKGROUND
Visceral leishmaniasis (VL) is among the world's most serious public health threats, causing immense human suffering and death. In Ethiopia, little is known about the barriers and facilitators of visceral leishmaniasis case management. This study aimed to explore such barriers and facilitators in the Amhara Regional State, Northwest Ethiopia.
METHODS METHODS
An exploratory qualitative study was conducted on 16 purposively selected patients and key informants from May 8 to June 2, 2023. The study participants were recruited using the maximum variation technique. The interviews were audio recorded, transcribed verbatim, and translated into English. Thematic analysis was employed using Atlas.ti 9 software with a blended approach of both deductive and inductive coding.
RESULTS RESULTS
The study identified a variety of issues that hinder the success of visceral leishmaniasis case management. Treatment centers face frequent interruptions of medicinal supplies, a lack of funding, and a lack of trained healthcare providers. A lack of support from health authorities, including weak supervision and feedback systems, is also a source of concern. Most patients receive treatments after significant delays, which is primarily due to low awareness, poor surveillance, and misdiagnosis by healthcare workers. The case management is further constrained by malnutrition, VL-HIV co-infection, and other comorbidities. Despite these issues, we found that effective collaboration between hospital units and VL treatment centers, acceptance by hospitals, and the caring attitude of healthcare workers play a positive role in facilitating the program's effectiveness.
CONCLUSIONS CONCLUSIONS
Despite the existence of certain efforts that facilitate the program's effectiveness, VL remains largely neglected, with little government attention or intervention. Such inattention is the root cause of most of the issues. Despite limited resources, most issues could be resolved with cost-effective strategies if health authorities at all levels have the will and commitment to do so.

Identifiants

pubmed: 39272019
doi: 10.1186/s12889-024-20055-1
pii: 10.1186/s12889-024-20055-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2500

Informations de copyright

© 2024. The Author(s).

Références

WHO. Leishmaniasis: background information. A brief history of the disease. World Health Organization: Geneva, Switzerland.; 2009.
World Health Organization. Leishmaniasis fact sheet 2023 [updated Jan 12. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
Wamai RG, Kahn J, McGloin J, Ziaggi G. Visceral leishmaniasis: a global overview. J Global Health Sci. 2020;2(1).
Ayele T, Ali A. The distribution of visceral leishmaniasis in Ethiopia. Am J Trop Med Hyg. 1984;33(4):548–52.
doi: 10.4269/ajtmh.1984.33.548 pubmed: 6476199
Kassahun A, Sadlova J, Dvorak V, Kostalova T, Rohousova I, Frynta D, et al. Detection of Leishmania Donovani and L. Tropica in Ethiopian wild rodents. Acta Trop. 2015;145:39–44.
doi: 10.1016/j.actatropica.2015.02.006 pubmed: 25700710
Leta S, Dao TH, Mesele F, Alemayehu G. Visceral leishmaniasis in Ethiopia: an evolving disease. PLoS Negl Trop Dis. 2014;8(9):e3131.
doi: 10.1371/journal.pntd.0003131 pubmed: 25188253 pmcid: 4154678
Gadisa E, Tsegaw T, Abera A, Elnaiem D-e, den Boer M, Aseffa A, Jorge A. Eco-epidemiology of visceral leishmaniasis in Ethiopia. Parasites Vectors. 2015;8(1):1–10.
doi: 10.1186/s13071-015-0987-y
Pires M, Wright B, Kaye PM, Da Conceicao V, Churchill RC. The impact of leishmaniasis on mental health and psychosocial well-being: a systematic review. PLoS ONE. 2019;14(10):e0223313.
doi: 10.1371/journal.pone.0223313 pubmed: 31622369 pmcid: 6797112
Jervis S, Chapman LA, Dwivedi S, Karthick M, Das A, Le Rutte EA, et al. Variations in visceral leishmaniasis burden, mortality and the pathway to care within Bihar, India. Parasites Vectors. 2017;10(1):1–17.
doi: 10.1186/s13071-017-2530-9
Welay GM, Alene KA, Dachew BA. Visceral leishmaniasis treatment outcome and its determinants in northwest Ethiopia. Epidemiol Health. 2016;39:e2017001.
doi: 10.4178/epih.e2017001 pubmed: 28092934 pmcid: 5343104
Ethiopia Federal Ministry of Health. Second Edition of National Neglected Tropical Diseases Master Plan, 2015/16–2019/20. Addis Ababa, 2016.
Ethiopia Federal Ministry of Health. Guidelines for diagnosis, treatment and prevention of Leishmaniasis in Ethiopia, 2nd Edition 2013. Addis Ababa, 2013.
Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016;5(1):1–15.
doi: 10.1186/s40249-016-0112-2
Uliana SR, T TRINCONI C, Coelho AC. Chemotherapy of leishmaniasis: present challenges. Parasitology. 2018;145(4):464.
doi: 10.1017/S0031182016002523 pubmed: 28103966
Alvar J, Beca-Martinez MT, Argaw D, Jain S, Aagaard-Hansen J. Social determinants of visceral leishmaniasis elimination in Eastern Africa. BMJ Glob Health. 2023;8(6).
Makau-Barasa LK, Ochol D, Yotebieng KA, Adera CB, de Souza DK. Moving from control to elimination of visceral leishmaniasis in East Africa. Front Trop Dis. 2022;3.
O H. J H. Visceral Leishmaniasis Control Strategies in Sudan: a review with recommendations. J Trop Dis. 2021;9(278).
Coulborn RM, Gebrehiwot TG, Schneider M, Gerstl S, Adera C, Herrero M, et al. Barriers to access to visceral leishmaniasis diagnosis and care among seasonal mobile workers in Western Tigray, Northern Ethiopia: a qualitative study. PLoS Negl Trop Dis. 2018;12(11):e0006778.
doi: 10.1371/journal.pntd.0006778 pubmed: 30408042 pmcid: 6224040
Gill N, Pandey D, Roy N, Dhingra N, Jainc S. Kala-Azar in India – progress and challenges towards its elimination as a public health problem. Wkly Epidemiol Rec. 2021;26:267–79.
Hailu T, Yimer M, Mulu W, Abera B. Challenges in visceral leishmaniasis control and elimination in the developing countries: a review. J Vector Borne Dis. 2016;53(3):193–8.
doi: 10.4103/0972-9062.191335 pubmed: 27681541
Burza S, Mahajan R, Sanz MG, Sunyoto T, Kumar R, Mitra G, Lima MA. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014;59(4):552–5.
doi: 10.1093/cid/ciu333 pubmed: 24814660
Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis. Infect Dis Poverty. 2018;7(1):108.
doi: 10.1186/s40249-018-0491-7 pubmed: 30340519 pmcid: 6194743
Druzian AF, de Souza AS, de Campos DN, Croda J, Higa MG Jr., Dorval ME, et al. Risk factors for death from visceral leishmaniasis in an urban area of Brazil. PLoS Negl Trop Dis. 2015;9(8):e0003982.
doi: 10.1371/journal.pntd.0003982 pubmed: 26274916 pmcid: 4537269
Diro E, Lynen L, Mohammed R, Boelaert M, Hailu A, van Griensven J. High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia. PLoS Negl Trop Dis. 2014;8(5):e2875.
doi: 10.1371/journal.pntd.0002875 pubmed: 24854196 pmcid: 4031116
Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl Trop Dis. 2014;8(6):e2869.
doi: 10.1371/journal.pntd.0002869 pubmed: 24968313 pmcid: 4072530
Scribbr. What Is a Case Study? Definition, Examples and Methods: Scribbr; 2023 [updated Jun 22. https://www.scribbr.com/methodology/case-study/
Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57.
doi: 10.1093/intqhc/mzm042 pubmed: 17872937
Patton MQ. Qualitative Research and evaluation methods: integrating theory and practice. 4th ed. Thousand Oaks, California: Sage; 2015.
Merriam SB, Tisdell EJ. Qualitative research: a guide to design and implementation. 4th ed. Wiley; 2016. p. 371.
Tolley EE, Ulin PR, Mack N, Robinson ET, Succop SM. Qualitative Methods in Public Health: a Field Guide for Applied Research 2. Wiley; 2016. p. 481.
Creswell JW, Creswell JD. Research Design: qualitative, quantitative, and mixed methods approaches. 5th ed. Thousand Oaks, California: SAGE; 2018.
Alvar J, den Boer M, Dagne DA. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action. Lancet Glob Health. 2021;9(12):e1763–9.
doi: 10.1016/S2214-109X(21)00392-2 pubmed: 34798033 pmcid: 8609279
WHO. Regional Strategic Framework for accelerating and sustaining elimination of kala-azar in the South-East Asia Region: 2022–2026. New Delhi: World Health Organization, Regional Office for South-East Asia; 2022.
Banjara MR, Hirve S, Siddiqui NA, Kumar N, Kansal S, Huda MM, et al. Visceral leishmaniasis clinical management in endemic districts of India, Nepal, and Bangladesh. J Trop Med. 2012;2012:126093.
doi: 10.1155/2012/126093 pubmed: 22649459 pmcid: 3357549
Joshi AB, Banjara MR, Chuke S, Kroeger A, Jain S, Aseffa A, Reeder JC. Assessment of the impact of implementation research on the visceral leishmaniasis (VL) elimination efforts in Nepal. PLoS Negl Trop Dis. 2023;17(11):e0011714.
doi: 10.1371/journal.pntd.0011714 pubmed: 37943733 pmcid: 10635428
Dahl EH, Hamdan HM, Mabrouk L, Matendechero SH, Mengistie TB, Elhag MS et al. Control of visceral leishmaniasis in East Africa: fragile progress, new threats. BMJ Glob Health. 2021;6(8).
Guan LR, Wu ZX. Historical experience in the elimination of visceral leishmaniasis in the plain region of Eastern and Central China. Infect Dis Poverty. 2014;3(1):10.
doi: 10.1186/2049-9957-3-10 pubmed: 24650707 pmcid: 4022322
Rijal S, Sundar S, Mondal D, Das P, Alvar J, Boelaert M. Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ. 2019;364:k5224.
doi: 10.1136/bmj.k5224 pubmed: 30670453 pmcid: 6340338
Omer M, Kroeger A, Joshi AB, Das ML, Younis LG, Singh VK, et al. Role of female community health volunteers for visceral leishmaniasis detection and vector surveillance in Nepal. Health Promot Perspect. 2020;10(1):50–8.
doi: 10.15171/hpp.2020.09 pubmed: 32104657 pmcid: 7036200
Al-Salem W, Herricks JR, Hotez PJ. A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for east African countries. Parasit Vectors. 2016;9(1):460.
doi: 10.1186/s13071-016-1743-7 pubmed: 27549162 pmcid: 4994383
Srinivasan R, Ahmad T, Raghavan V, Kaushik M, Pathak R. Positive Influence of Behavior Change Communication on Knowledge, attitudes, and practices for visceral Leishmaniasis/Kala-azar in India. Glob Health Sci Pract. 2018;6(1):192–209.
doi: 10.9745/GHSP-D-17-00087 pubmed: 29386327 pmcid: 5878072
Lim D, Banjara MR, Singh VK, Joshi AB, Gurung CK, Das ML, et al. Barriers of visceral leishmaniasis reporting and surveillance in Nepal: comparison of governmental VL-program districts with non-program districts. Trop Med Int Health. 2019;24(2):192–204.
doi: 10.1111/tmi.13189 pubmed: 30565348
Hirve S, Kroeger A, Matlashewski G, Mondal D, Banjara MR, Das P, et al. Towards elimination of visceral leishmaniasis in the Indian subcontinent-translating research to practice to public health. PLoS Negl Trop Dis. 2017;11(10):e0005889.
doi: 10.1371/journal.pntd.0005889 pubmed: 29023446 pmcid: 5638223
Boettcher JP, Siwakoti Y, Milojkovic A, Siddiqui NA, Gurung CK, Rijal S, et al. Visceral leishmaniasis diagnosis and reporting delays as an obstacle to timely response actions in Nepal and India. BMC Infect Dis. 2015;15:43.
doi: 10.1186/s12879-015-0767-5 pubmed: 25656298 pmcid: 4335691
Gidey K, Belay D, Hailu BY, Kassa TD, Niriayo YL. Visceral Leishmaniasis Treatment Outcome and Associated factors in Northern Ethiopia. Biomed Res Int. 2019;2019:3513957.
doi: 10.1155/2019/3513957 pubmed: 31531350 pmcid: 6719273
Kansal S, Chakravarty J, Kumar A, Malaviya P, Boelaert M, Hasker E, et al. Risk factors associated with defaulting from visceral leishmaniasis treatment: analysis under routine programme conditions in Bihar, India. Trop Med Int Health. 2017;22(8):1037–42.
doi: 10.1111/tmi.12906 pubmed: 28594453 pmcid: 6345645
Grifferty G, Shirley H, McGloin J, Kahn J, Orriols A, Wamai R. Vulnerabilities to and the socioeconomic and psychosocial impacts of the leishmaniases: a review. Res Rep Trop Med. 2021;12:135–51.
pubmed: 34188584 pmcid: 8236266

Auteurs

Yared Mulu Gelaw (YM)

Department of Health Systems Management and Health Economics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia. yareadmulu@gmail.com.
Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes, France. yareadmulu@gmail.com.

Jean-Pierre Gangneux (JP)

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes, France.

Getu Degu Alene (GD)

Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.

Florence Robert-Gangneux (F)

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes, France.

Adisu Abebe Dawed (AA)

Amhara Regional Health Bureau, Neglected Tropical Disease unit, Bahir Dar, Ethiopia.

Mohammed Hussien (M)

Department of Health Systems Management and Health Economics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.

Wendemagegn Enbiale (W)

Department of Dermatovenerology, School of Medicine, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH